1070882-67-5 Usage
Uses
Used in Organic Synthesis:
3-Bromo-5-(3-methylphenyl)pyridine is utilized as an intermediate in organic synthesis for the creation of diverse compounds. Its unique structure allows it to serve as a key component in the formation of new chemical entities with potential applications across various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-Bromo-5-(3-methylphenyl)pyridine is employed as an intermediate in the production of biologically active molecules. Its role in drug development is crucial, as it contributes to the synthesis of new drugs with potential therapeutic effects.
Used in Medicinal Chemistry:
3-Bromo-5-(3-methylphenyl)pyridine holds significance in the field of medicinal chemistry due to its potential applications in the development of new drugs. Its unique structural features make it a promising candidate for the design and synthesis of compounds with therapeutic properties, thereby expanding the scope of treatment options for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1070882-67-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,0,8,8 and 2 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1070882-67:
(9*1)+(8*0)+(7*7)+(6*0)+(5*8)+(4*8)+(3*2)+(2*6)+(1*7)=155
155 % 10 = 5
So 1070882-67-5 is a valid CAS Registry Number.
1070882-67-5Relevant articles and documents
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 0599; 0600, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
